Numerai’s Charles River Laboratories CRL Stock Holding History

Numerai’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-12,617	Closed	-$1.9M	–	495
2025 Q1	$1.9M	Buy	12,617 +4,005	+47%	+$671K	0.36%	71
2024 Q4	$1.59M	Buy	+8,612	New	+$1.66M	0.44%	69

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Numerai's CRL Position: Q2 2025 in Review

Numerai sold out of Charles River Laboratories (CRL) in Q2 2025, closing a stake of 12,617 shares — an estimated $1.9M sold.

Numerai first reported a position in CRL in Q4 2024 and held it in 2 quarters. The position peaked at $1.9M in Q1 2025. 519 funds tracked by Wall St. Rank hold CRL as of Q2 2025.

Numerai reported no remaining Charles River Laboratories position as of Q2 2025 after selling out during the quarter.
Numerai sold 12,617 Charles River Laboratories shares in Q2 2025, an estimated $1.9M.
Numerai first reported a position in Charles River Laboratories in Q4 2024 and held it in 2 quarters.
Numerai's Charles River Laboratories position peaked at $1.9M in Q1 2025.
519 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2025.

Based on Numerai's 13F filing for Q2 2025, filed 14 Aug 2025.